IP Library › Granted Patent US 8,444,980
Granted Patent B2
US 8,444,980 · App. 13/175,748 · Granted May 21, 2013

Therapeutic use of anti-CS1 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,444,980
App. No.
13/175,748
Granted
May 21, 2013
Kind
B2
Abstract

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Claims (40)

1. A method of treating multiple myeloma, comprising administering to a patient in need thereof a therapeutically effective amount of a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.

2. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment inhibits immunoglobulin secretion.

3. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is humanized.

4. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces antibody-dependent cellular cytotoxicity (“ADCC”) of cells expressing said protein encoded by SEQ ID NO:1.

5. The method of claim 4 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 40% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.

6. The method of claim 4 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 60% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.

7. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is an IgG 1 .

8. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment has a low level of or lacks fucose.

9. The method of claim 1 , further comprising administering velcade to the patient.

10. The method of claim 1 , further comprising administering to the patient an immunosuppressive drug.

11. The method of claim 1 , further comprising administering to the patient an immunodulator.

12. The method of claim 11 , further comprising administering to the patient an immunosuppressive drug.

13. The method of claim 10 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunosuppressive drug.

14. The method of claim 10 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunosuppressive drug.

15. The method of claim 11 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunomodulator.

16. The method of claim 11 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunomodulator.

17. The method of claim 12 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered after the immunosuppressive drug and the immunomodulator.

18. The method of claim 12 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered in combination with the immunosuppressive drug and the immunomodulator.

19. The method of claim 1 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is administered over a series of treatments.

20. A method of treating multiple myeloma, comprising administering to a patient in need thereof a therapeutically effective amount of a conjugate compound comprising a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment linked to an effector moiety, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.

21. The method of claim 20 , wherein the effector moiety is a cytotoxic agent.

22. The method of claim 20 , wherein the effector moiety is a detection moiety, an activatable moiety, a chemotherapeutic agent, a lipase, an antibiotic, a chemoattracting agent, an immune modulator or a radioisotope.

23. The method of claim 20 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment inhibits immunoglobulin secretion.

24. The method of claim 20 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is humanized.

25. The method of claim 20 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces antibody-dependent cellular cytotoxicity (“ADCC”) of cells expressing said protein encoded by SEQ ID NO: 1.

26. The method of claim 25 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 40% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.

27. The method of claim 25 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment induces at least 60% cytotoxicity of cells expressing said protein encoded by SEQ ID NO:1.

28. The method of claim 20 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment is an IgG 1 .

29. The method of claim 20 , wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment has a low level of or lacks fucose.

30. The method of claim 20 , further comprising administering velcade to the patient.

31. The method of claim 20 , further comprising administering to the patient an immunosuppressive drug.

32. The method of claim 20 , further comprising administering to the patient an immunodulator.

33. The method of claim 32 , further comprising administering to the patient an immunosuppressive drug.

34. The method of claim 31 , wherein the conjugate compound is administered after the immunosuppressive drug.

35. The method of claim 31 , wherein the conjugate compound is administered in combination with the immunosuppressive drug.

36. The method of claim 32 , wherein the conjugate compound is administered after the immunomodulator.

37. The method of claim 32 , wherein the conjugate compound is administered in combination with the immunomodulator.

38. The method of claim 33 , wherein the conjugate compound is administered after the immunosuppressive drug and the immunomodulator.

39. The method of claim 33 , wherein the conjugate compound is administered in combination with the immunosuppressive drug and the immunomodulator.

40. The method of claim 21 , wherein the conjugate compound is administered over a series of treatments.

Assignments (1)
CHANGE OF NAME Recorded Jan 11, 2013
From: ABBOTT BIOTHERAPEUTICS CORP.
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029612/0275 →